At a glance
ClinicalIndex Comparison Record- ✓Confirmed diagnosis of idiopathic pulmonary fibrosis (IPF)
- ✓Daily unrestricted access to smartphone or tablet device at home
- ✓Demonstrated understanding of protocol and correct use of Spirobank Smart spirometer and patientMpower platform
- ✓Able and willing to perform spirometry every day at home
- ✕Significant confusion or any concomitant medical condition limiting ability to record symptoms or use home spirometer regularly
- ✕New prescription of antifibrotic therapy (pirfenidone, nintedanib) within 4 weeks before baseline visit
- ✕Recent IPF exacerbation or clinically significant change in medical condition within 4 weeks before baseline visit
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Crossover Study of Self-monitoring of Symptoms and Spirometry Via the patientMpower Platform in Patients With Idiopathic Pulmonary Fibrosis
In Brief
A clinical study evaluating patientMpower platform and usual care for Idiopathic Pulmonary Fibrosis. Completed, enrolled 7 participants across 1 site.
Detailed Summary
Pilot-scale, open-label, fixed-order, two-period crossover study in idiopathic pulmonary fibrosis (IPF) over 16 weeks. Patients will use an electronic health journal (patientMpower platform) to record treatment compliance, forced vital capacity (FVC; daily), impact of IPF on daily life (weekly) and other symptoms. Objectives are to characterise acceptability of patientMpower platform from patient \& healthcare professional perspective, impact of active engagement and self-monitoring using patientMpower platform on Patient Reported Outcome Measures (PROMs) in IPF, impact of patientMpower platform on medication compliance and correlation between patient-reported PROMs \& FVC and clinical outcomes.
Study Details
Timeline
Interventions
electronic health journal for patient to record compliance, spirometry, impact on daily life and symptoms
usual care